not really - but I think the screen flow is easier. The information is still dated, but I do like to read the ppt Corporate Presentation. The numbers thrown out by TLAON are very convincing, assuming all goes as plan. Even if Marqibo gets a fraction of the potential market I would estimate the market cap should be at least $1.6 billion. I would also expect that Menadione would double that.
Dr. Dietcher is a good public speaker - I miss not having a corporate CC for the first quarter results not that there would have been significant amount of development since the last CC. But a business update is what everyone is interested in.
bhakes, I am trying to understand, the enrollment goal for the Menadione phase II trial was 40, can you explain how they can stop at 27 and the test still be valid? Especially since it is a double blinded test.